Effect of topical application of melatonin on serum levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) in patients with type 1 or type 2 diabetes and periodontal disease

Cutando, Antonio; Montero, Javier; Diego, Rafael Gómez-de; Ferrera, María-José; López-Valverde, Antonio

doi:10.4317/jced.52604

Cited by 44 publications

(74 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the early stage of periodontal disease, the inflammatory response is localized only in the gingival tissue, but if left untreated, gingivitis can advance to periodontitis. Proinflammatory cytokines, such as TNF‐α, IL‐1β, IL‐6, and IL‐8, contribute to the development of periodontitis and can serve as markers to evaluate the success of periodontal therapy 29 , 30 . Based on the LPS and ligature‐induced rat periodontitis model, it was further determined that BTZ significantly reduced expression of TNF‐α, IL‐1β, IL‐6, and IL‐8 in periodontal tissue (Figs.…”

Section: Discussionmentioning

confidence: 99%

The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats

Jiang

Song

et al. 2017

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats

Jiang

Song

et al. 2017

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…In dentistry, researchers tried to take advantage of melatonin's effect to improve oral cavity health . The use of melatonin in treating periodontal disease is hopeful . It is physiologically present in saliva and in crevicular fluid; patients affected by periodontitis show a statistically significant reduction in salivary melatonin levels .…”

Section: Introductionmentioning

confidence: 99%

Melatonin as host modulating agent supporting nonsurgical periodontal therapy in patients affected by untreated severe periodontitis: A preliminary randomized, triple‐blind, placebo‐controlled study

Tinto¹,

Sartori²,

Pizzi³

et al. 2019

J of Periodontal Research

View full text Add to dashboard Cite

Objectives The aim of the current clinical trial was to evaluate if the oral supplementation of melatonin after nonsurgical periodontal therapy (NSPT) determined a better periodontal healing than NSPT alone, in patients affected by untreated severe periodontitis. Background Melatonin's anti‐inflammatory, antioxidant and immunomodulatory capacities, together with its pharmacokinetic and pharmacodynamic profiles are key characteristics that justify the therapeutic use for the treatment of periodontitis. Methods This is a randomized, triple‐blind, placebo‐controlled study. Twenty patients were blindly randomized either to melatonin or placebo group. The melatonin group received NSPT and melatonin capsules 1 mg per day for 1 month, while the placebo, NSPT, and placebo capsules for 1 month. The patients were evaluated at baseline and 6 months after. Mean change from baseline probing depth (PD) was the primary outcome; site of probing was used as unit of analysis; FMBS (%) and FMPS (%) were also calculated. Mann‐Whitney test was used to evaluate statistical significance (α = 0.05). Results Melatonin was well tolerated by all patients. Both treatments were effective in reducing PD, but no statistical difference was found when comparing posttreatment PD (probing all sites), P = .62. When considering the primary outcome, melatonin administration resulted in greater mean PD change at 6 months if compared to control group: for 4‐5 mm sites 1.86 (0.81) vs 1.04 (0.69), P = .00001 and for sites >5 mm 3.33 (1.43) vs 2.11 (0.96), P = .00012. No difference was found for FMBS and FMPS. Conclusion Current study, within its limitations, concluded that oral administration of melatonin (1 mg per day for 30 days) after one‐stage full mouth NSPT determined a greater change from baseline PD if compared to NSPT alone, in untreated stage III periodontitis. This could provide a non‐pharmacological support to improve periodontal healing of periodontal sites after NSPT.

show abstract

“…), periodontal diseases (Cutando et al . ), dental implants (Tresguerres et al . ) and acute pulpitis (Li et al .…”

Section: Introductionmentioning

confidence: 99%

Anti‐inflammatory and antiresorptive functions of melatonin on experimentally induced periapical lesions

Sarıtekin¹,

Kaya²,

Aşçı³

et al. 2019

Int Endodontic J

View full text Add to dashboard Cite

Aim To investigate the effects of systemically administered melatonin on inflammation and alveolar bone resorption in rats with experimentally induced periapical lesions. Methodology Thirty adult Sprague Dawley rats were divided equally into negative, positive control and melatonin groups. The pulp chambers of their mandibular first molars were exposed to the oral environment to induce experimental periapical lesions in the positive control and melatonin groups. The melatonin group received daily intraperitoneal injections of melatonin at a dose of 10 mg kg−1. After 21 days, the animals were euthanized; the hemi‐mandible parts were prepared for radiological, histopathological, immunohistochemical (IL‐1β, RANK, RANKL, OPG and tartrate‐resistant acid phosphatase (TRAP) and Brown–Brenn (bacteria) evaluations. Data were analysed by Kruskal–Wallis (for non‐parametric data) and one‐way anova tests (for parametric data) (P < 0.05). Results The area of radiographic periapical bone loss was significantly smaller in rats that were given daily intraperitoneal injections of melatonin (P < 0.01). The histopathological scores of the melatonin group were significantly lower than those of positive control group (P < 0.01). Histomorphometrically, the area of periapical bone loss in the melatonin group was significantly smaller than the positive control group (P < 0.01). The expression of IL1‐β, RANK and RANKL was significantly higher in the positive control group, whereas OPG was significantly higher in the melatonin group (P < 0.01). The number of osteoclasts was significantly greater in the positive control group by TRAP staining analyses (P < 0.01). The scores for bacteria localization using Brown–Brenn staining in the melatonin group was significantly lower than that of the positive control group (P < 0.01). Conclusions Melatonin demonstrated antiresorptive effects on bone associated with experimentally induced periapical lesions in rats via its anti‐inflammatory activity. Further studies are necessary to evaluate its possible effects on the healing of periapical lesions.

show abstract

Effect of topical application of melatonin on serum levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) in patients with type 1 or type 2 diabetes and periodontal disease

Cited by 44 publications

References 29 publications

The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats

The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats

Melatonin as host modulating agent supporting nonsurgical periodontal therapy in patients affected by untreated severe periodontitis: A preliminary randomized, triple‐blind, placebo‐controlled study

Anti‐inflammatory and antiresorptive functions of melatonin on experimentally induced periapical lesions

Contact Info

Product

Resources

About